RESEARCH ARTICLE


A Simplified Approach to the Diagnosis of Atypical HUS: Clinical Considerations and Practical Implications



Arif Asif *, 1, Tushar Vachharajani 2, Loay Salman 3, Ali Nayer 3
1 Division of Nephrology and Hypertension, Albany Medical College, Albany, NY, USA
2 Division of Nephrology and Hypertension W.G. (Bill) Hefner Veterans Affairs Medical Center, Salisbury, NC, USA
3 Division of Nephrology and Hypertension, University of Miami Miller School of Medicine, Miami, FL, USA


Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 2053
Abstract HTML Views: 645
PDF Downloads: 318
ePub Downloads: 166
Total Views/Downloads: 3182
Unique Statistics:

Full-Text HTML Views: 918
Abstract HTML Views: 354
PDF Downloads: 247
ePub Downloads: 124
Total Views/Downloads: 1643



© Asif et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Division of Nephrology and Hypertension, Albany Medical College, 25 Hackett Blvd. Albany, NY 12208, USA; Tel: 518-262-0769; E-mail: asifa@mail.amc.edu


Abstract

Although rare, atypical hemolytic-uremic syndrome (aHUS) carries a high morbidity and mortality. Widespread microvascular thrombosis, thrombocytopenia and microangiopathic hemolytic anemia are the hallmark of aHUS. Virtually any organ (particularly the kidney) can be a target for the devastating effects of this syndrome. Uncontrolled activation of the alternative pathway of the complement system lies at the heart of the pathogenesis of aHUS. While significant advances have been made in our understanding of aHUS, establishing timely diagnosis of this syndrome has been challenging. This, in part, is due to the absence of a sensitive and specific diagnostic test and a relatively lack of our familiarity with the syndrome. With the recent success and approval of a humanized monoclonal antibody (eculizumab) in the treatment of aHUS, prompt and accurate diagnosis is of paramount importance to limit the target organ injury. This article presents a simplified approach to establishing the diagnosis of aHUS.

Keywords: Atypical hemolytic uremic syndrome, eculizumab, thrombotic microangiopathy, thrombotic thrombocytopenic purpura..